Right Turn Show - Application of Dapagliflozin & its Combinations in Specialty Settings

#dapagliflozin #rightturnhow #dapaturn #diabetes

Presenting Episode 2 of the Right Turn Show, in this episode, insights from leading experts are explored on the practical application of dapagliflozin and its combinations. The previous episode focused on the consideration of dapagliflozin in specialty care settings. Building on that, this episode focusses on the various Fixed Dose Combinations (FDCs) of dapagliflozin.

Dapagliflozin remains a preferred therapy among clinicians for managing Type 2 Diabetes Mellitus (T2DM), while also offering significant benefits in the treatment of heart failure and chronic kidney disease (CKD).

This episode features two distinguished experts, Dr J.C. Mohan, a prominent cardiologist and Chairman of the Institute of Heart & Vascular Diseases at Jaipur Golden Hospital, New Delhi. Prof. Abdul Hamid Zargar, a leading endocrinologist renowned for his expertise in diabetes and endocrine care from Srinagar, Jammu & Kashmir.

In this episode they will address the following key questions:
1) Prioritization of therapies for patients with cardiovascular risk, particularly those with heart failure or established atherosclerotic cardiovascular disease (ASCVD)?
2) Prioritization of therapies between these combinations (monotherapy, dual FDC, or triple FDC) when managing T2DM patients with different stages of glycemic control needs?
3) Differentiate between using Dapagliflozin monotherapy, Dapagliflozin Sitagliptin dual FDC, and Dapagliflozin Sitagliptin Metformin triple FDC in clinical practice?
4) Approach to counselling patients on the added benefits of Dapagliflozin-based combinations beyond glycemic control, such as weight reduction and blood pressure management?
5) Given the rising prevalence of chronic kidney disease (CKD) in T2DM patients, how does the inclusion of Dapagliflozin in combination therapies influence decision-making for high-risk patients?